Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

The deception and fallacies of sponsored randomized prospective double-blinded clinical trials: the bisphosphonate research example.

Marx RE.

Int J Oral Maxillofac Implants. 2014 Jan-Feb;29(1):e37-44. doi: 10.11607/jomi.te40.

PMID:
24451886
2.

Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.

Kharazmi M, Hallberg P, Warfvinge G, Michaƫlsson K.

Rheumatology (Oxford). 2014 Oct;53(10):1911-3. doi: 10.1093/rheumatology/keu286. Epub 2014 Aug 6. No abstract available.

PMID:
25099769
3.

FPIN's clinical inquiries. Risks of bisphosphonate use.

Scott MA, Meadowcraft L, Skolnik D.

Am Fam Physician. 2013 Nov 15;88(10):697, 702. Review. No abstract available.

4.

Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project.

Edwards BJ, Bunta AD, Lane J, Odvina C, Rao DS, Raisch DW, McKoy JM, Omar I, Belknap SM, Garg V, Hahr AJ, Samaras AT, Fisher MJ, West DP, Langman CB, Stern PH.

J Bone Joint Surg Am. 2013 Feb 20;95(4):297-307. doi: 10.2106/JBJS.K.01181. Review.

5.

Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.

Kharazmi M, Persson U, Warfvinge G.

J Oral Maxillofac Surg. 2012 Dec;70(12):2793-7. doi: 10.1016/j.joms.2012.01.025. Epub 2012 May 19.

PMID:
22609135
6.

Skeletal complications of bisphosphonate use: what the radiologist should know.

Haworth AE, Webb J.

Br J Radiol. 2012 Oct;85(1018):1333-42. doi: 10.1259/bjr/99102700. Review.

7.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
8.

[Controlled randomized clinical trials].

Jaillon P.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8. French.

PMID:
18225427
9.

Awareness and education of patients receiving bisphosphonates.

Bauer JS, Beck N, Kiefer J, Stockmann P, Wichmann M, Eitner S.

J Craniomaxillofac Surg. 2012 Apr;40(3):277-82. doi: 10.1016/j.jcms.2011.04.011. Epub 2011 May 25.

PMID:
21612939
10.

Bisphosphonates in multiple myeloma: a network meta-analysis.

Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, Kumar A, Djulbegovic B.

Cochrane Database Syst Rev. 2012 May 16;5:CD003188. doi: 10.1002/14651858.CD003188.pub3. Review.

PMID:
22592688
11.

Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday.

McClung M, Harris ST, Miller PD, Bauer DC, Davison KS, Dian L, Hanley DA, Kendler DL, Yuen CK, Lewiecki EM.

Am J Med. 2013 Jan;126(1):13-20. doi: 10.1016/j.amjmed.2012.06.023. Epub 2012 Nov 20. Review.

PMID:
23177553
12.

Bisphosphonate-related osteonecrosis of the jaw in patients with oral bisphosphonate exposure: clinical course and outcomes.

O'Ryan FS, Lo JC.

J Oral Maxillofac Surg. 2012 Aug;70(8):1844-53. doi: 10.1016/j.joms.2011.08.033. Epub 2012 May 16.

PMID:
22595135
13.

Safety of bisphosphonates.

Orozco C, Maalouf NM.

Rheum Dis Clin North Am. 2012 Nov;38(4):681-705. doi: 10.1016/j.rdc.2012.09.001. Review.

PMID:
23137577
14.

Bisphosphonate therapy for children and adolescents with secondary osteoporosis.

Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D.

Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005324. Review.

PMID:
17943849
15.

Bisphosphonates for osteoporosis in primary biliary cirrhosis.

Rudic JS, Giljaca V, Krstic MN, Bjelakovic G, Gluud C.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD009144. doi: 10.1002/14651858.CD009144.pub2. Review.

PMID:
22161446
16.

A prospective clinical trial for assessing the efficacy of a minimally invasive protocol in patients with bisphosphonate-associated osteonecrosis of the jaws.

Moretti F, Pelliccioni GA, Montebugnoli L, Marchetti C.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2011 Dec;112(6):777-82. doi: 10.1016/j.tripleo.2011.07.004. Epub 2011 Oct 14.

PMID:
22000426
17.

Incidence of serious side effects with intravenous bisphosphonate: a clinical audit.

Powell D, Bowler C, Roberts T, Garton M, Matthews C, McCall I, Davie M.

QJM. 2012 Oct;105(10):965-71. Epub 2012 Jun 28.

18.

Safety of long-term bisphosphonate therapy for the management of osteoporosis.

Lewiecki EM.

Drugs. 2011 Apr 16;71(6):791-814. doi: 10.2165/11585470-000000000-00000. Review.

PMID:
21504254
19.

Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.

Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C.

Clin Drug Investig. 2013 Feb;33(2):117-22. doi: 10.1007/s40261-012-0041-1.

PMID:
23184667
20.

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, de Papp A, Bauer DC; Fracture Intervention Trial Steering Committee; HORIZON Pivotal Fracture Trial Steering Committee.

N Engl J Med. 2010 May 13;362(19):1761-71. doi: 10.1056/NEJMoa1001086. Epub 2010 Mar 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk